Kiniksa CAO sells 6,625 shares under 10b5-1 plan

Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. After this transaction, he directly holds 27,418 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 6,625 shares

Net Sell 1 txn

Insider Megna Michael R

Role CHIEF ACCOUNTING OFFICER

Sold 6,625 shs ($309K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Share	6,625	$46.69	$309K

Holdings After Transaction: Class A Ordinary Share — 27,418 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.

Key Figures

Shares sold: 6,625 shares Sale price per share: $46.69 per share Shares held after transaction: 27,418 shares +1 more

4 metrics

Shares sold 6,625 shares Class A Ordinary Shares sold on April 9, 2026

Sale price per share $46.69 per share Open-market sale price for Kiniksa Class A Ordinary Shares

Shares held after transaction 27,418 shares Direct holdings of Michael R. Megna after the sale

Transactions reported 1 sale transaction Single open-market sale in this Form 4

Key Terms

Rule 10b5-1, open-market sale, Class A Ordinary Share, Form 4

4 terms

Rule 10b5-1 regulatory

"This transaction was effected pursuant to a 10b5-1 plan executed"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Ordinary Share financial

""security_title": "Class A Ordinary Share""

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KNSA report for Michael R. Megna?

Kiniksa’s chief accounting officer Michael R. Megna reported selling 6,625 Class A Ordinary Shares. The sale occurred on April 9, 2026 at an average price of $46.69 per share, and was executed under a pre-arranged Rule 10b5-1 trading plan.

At what price were Kiniksa (KNSA) shares sold in this Form 4?

The reported Kiniksa shares were sold at an average price of $46.69 per share. This price applies to 6,625 Class A Ordinary Shares sold in an open-market transaction disclosed by chief accounting officer Michael R. Megna on April 9, 2026.

How many KNSA shares does the insider hold after this sale?

After the reported transaction, Michael R. Megna holds 27,418 Class A Ordinary Shares directly. This post-transaction balance reflects his remaining position following the open-market sale of 6,625 shares at $46.69 per share disclosed in the Form 4.

Was the KNSA insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged schedules for trading, designed to allow insiders to sell shares over time without making ad hoc timing decisions.

Who is the insider involved in this Kiniksa (KNSA) Form 4 filing?

The Form 4 identifies Michael R. Megna, Kiniksa Pharmaceuticals International, plc’s chief accounting officer, as the reporting person. He reported a direct open-market sale of 6,625 Class A Ordinary Shares and continues to hold 27,418 shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	04/09/2026		S(1)		6,625	D	$46.69	27,418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.

	/s/ Douglas Barry, Attorney-in-Fact	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)